Research programme: vascular disrupting agents - Angiogene Pharmaceuticals
Alternative Names: ANG-501; ANG500 seriesLatest Information Update: 30 Apr 2021
At a glance
- Originator Angiogene Pharmaceuticals
- Class
- Mechanism of Action Vascular disrupting agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer